NCT07470203 2026-03-13
Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer
Peking University Cancer Hospital & Institute
Not yet recruiting
Clinical Trials
5 trialsNCT07179939 2025-09-18
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
Fudan University
Phase 2 Not yet recruiting
NCT06973525 2025-08-05
HER2-DM-NACT
Hebei Medical University Fourth Hospital
Phase 2 Not yet recruiting
NCT06718335 2024-12-11
Pyrotinib in HER2-positive Early Breast Cancer
Yunnan Cancer Hospital
Phase NA Not yet recruiting
NCT04158856 2019-11-12
SHERO
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting